New @nature.com
The brains of Super Agers produce more neurons than people some 50 years younger, a neurogenesis resilient signature linked to exceptional cognitive health and memory skills
nature.com/articles/s41...
New study in @nature.com reveals mutational impact in normal tissue of things like smoking, drinking, & #cancer treatments. Median 25% of mutations caused by such "exogenous" factors. Smoking a doozy for the lungs: each pack year = 20 mutations per cell! www.nature.com/articles/s41...
In this cohort study, most health-related social needs (HRSNs) were associated with ED visits, with strongest associations for housing instability and transportation. ja.ma/3N1MbSM
A figure showing invasive disease–free survival with trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1).
In patients with HER2-positive early breast cancer and residual disease after neoadjuvant therapy, trastuzumab deruxtecan improved invasive disease–free survival but carried a risk of interstitial lung disease. Full DESTINY-Breast05 phase 3 trial results: nej.md/4an3Az2
Particularly on the heels of the remarkable data out of Australia of ZERO cervical cancer dx in people <25 (in 2021), it's shocking to me that these findings on one dose of the #hpvvaccine haven't received more attention: www.nejm.org/doi/abs/10.1... #prevention #cancer
Dr. Heather Landau, a cellular therapist at MSK, recently presented findings from a phase 1 clinical trial for patients with light chain (AL) amyloidosis with at the 2025 @ash.hematology.org Annual Meeting. #ASH25
bit.ly/4aBRoKM
18% overall w/ G2+ LV systolic dysfunction. No sig benefit w/ ACEi before LV systolic dysfunction but possible protective effect w/ earlier initiation. (2/2) #ASH25
A new clinical trial funded by @su2c.bsky.social and J&J for people with a difficult-to-treat disease called AL-amyloidosis. The trial, led by Dr. Suzanne Lentzsch of @columbiamed.bsky.social, will test the combination of (1/2) www.sciencedirect.com/science/arti...
